Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RegStem
- Development stage
- Phase 1
- Lead developer
- EMO Biomedicine
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
RegStem is an autologous mesenchymal stromal cell (MSC) therapy developed by EMO Biomedicine for the treatment of knee osteoarthritis. The product is derived from MSCs isolated from the patient's own infrapatellar fat pad, which are expanded ex vivo to reach a therapeutic concentration. Once expanded, the cells are administered via intra-articular injection into the joint cavity. The mechanism of action involves the cells' ability to promote tissue repair, regeneration, and anti-inflammatory responses, as well as their potential for chondrogenesis to restore damaged cartilage in the osteoarthritic knee.
- Brand names
- RegStem
- Other names
- autologous mesenchymal stromal cell productinfrapatellar fat pad mesenchymal stem cellsIF-MSC
Beyond the preview
Go deeper on RegStem.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RegStem.